Drugs / Protein based pneumococcal vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04087460 | Apr 2020 → May 2021 | pneumonia | CanSino Biologics Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Protein based pneumococcal vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04087460 ↗ |
| Known as | PBPV | “0.2mL,Intramuscular other name:PBPV” NCT04087460 ↗ |
| Modality | Vaccine | “The aim of the study is to preliminary evaluate the safety and immunogenicity of PBPV vaccine compared to placebo” NCT04087460 ↗ |
| Route | Intramuscular | “0.2mL,Intramuscular other name:PBPV” NCT04087460 ↗ |